GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HAEMATO AG (XTER:HAEK) » Definitions » EV-to-EBIT

HAEMATO AG (XTER:HAEK) EV-to-EBIT : 6.92 (As of May. 12, 2024)


View and export this data going back to 2005. Start your Free Trial

What is HAEMATO AG EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, HAEMATO AG's Enterprise Value is €88.6 Mil. HAEMATO AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €12.8 Mil. Therefore, HAEMATO AG's EV-to-EBIT for today is 6.92.

The historical rank and industry rank for HAEMATO AG's EV-to-EBIT or its related term are showing as below:

XTER:HAEK' s EV-to-EBIT Range Over the Past 10 Years
Min: -161.34   Med: 9.11   Max: 21.62
Current: 4.33

During the past 13 years, the highest EV-to-EBIT of HAEMATO AG was 21.62. The lowest was -161.34. And the median was 9.11.

XTER:HAEK's EV-to-EBIT is ranked better than
92.08% of 669 companies
in the Drug Manufacturers industry
Industry Median: 17.95 vs XTER:HAEK: 4.33

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. HAEMATO AG's Enterprise Value for the quarter that ended in Jun. 2023 was €98.0 Mil. HAEMATO AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €12.8 Mil. HAEMATO AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 13.07%.


HAEMATO AG EV-to-EBIT Historical Data

The historical data trend for HAEMATO AG's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HAEMATO AG EV-to-EBIT Chart

HAEMATO AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.16 -151.85 -25.92 9.22 5.55

HAEMATO AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 9.22 - 5.55 -

Competitive Comparison of HAEMATO AG's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, HAEMATO AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HAEMATO AG's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HAEMATO AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where HAEMATO AG's EV-to-EBIT falls into.



HAEMATO AG EV-to-EBIT Calculation

HAEMATO AG's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=88.594/12.805
=6.92

HAEMATO AG's current Enterprise Value is €88.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HAEMATO AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €12.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HAEMATO AG  (XTER:HAEK) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

HAEMATO AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=12.805/98.006992
=13.07 %

HAEMATO AG's Enterprise Value for the quarter that ended in Jun. 2023 was €98.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HAEMATO AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €12.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HAEMATO AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of HAEMATO AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


HAEMATO AG (XTER:HAEK) Business Description

Traded in Other Exchanges
Address
Lilienthalstrasse 5c, Schonefeld, DEU, D-12529
HAEMATO AG is a Germany based pharmaceutical company. It provides pharmaceuticals for the care of chronically ill people. The firm is engaged in the sale of generic and EU (European countries) import drugs. It is focused on patented and non-patented medicinal products. The company product portfolio includes human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), neurology, oncology, rheumatology, and urology. Geographically, it operates only in Germany.

HAEMATO AG (XTER:HAEK) Headlines

No Headlines